Journal: Stem Cell Research & Therapy
Article Title: MSC-exosomes pretreated by Danshensu extracts pretreating to target the hsa-miR-27a-5p and STAT3-SHANK2 to enhanced antifibrotic therapy
doi: 10.1186/s13287-025-04181-0
Figure Lengend Snippet: The expression of STAT3/HIF-1α/VEGFA in vitro. A Western blot images for STAT3 (T721 and S727), HIF-1α, VEGFA expression with different treatments: (a) Control, (b) PD, (c) PD + DSS-Exo, (d) PD + DSS-Exo + Colivelin, (e) PD + Colivelin, (f) PD + DSS-Exo + Fenbendazole-d3, (g) PD + Fenbendazole-d3, (h) PD + DSS-Exo + Colivelin + Fenbendazole-d3, (i) PD + Colivelin + Fenbendazole-d3. B – E Quantitative analysis of the relative expression levels of proteins: B STAT3 (T721), C STAT3 (S727), D HIF-1α, E VEGFA. F Western blot images for STAT3 (T721 and S727), HIF-1α, and VEGFA expression with different treatments: (a) Control, (b) PD, (c) PD + DSS-Exo, (d) PD + DSS-Exo + Stattic + LW6, (e) PD + Stattic + LW6, (f) PD + DSS-Exo + Stattic, (g) PD + Stattic, (h) PD + DSS-Exo + LW6, (i) PD + LW6. G – J Quantitative analysis of the relative expression levels of proteins: G STAT3 (T721), H STAT3 (S727), I HIF-1α, J VEGFA. ns: P > 0.05; *: P < 0.05; **: P < 0.01;***: P < 0.001; #: P < 0.0001
Article Snippet: The following primary antibodies were used: Rabbit polyclonal VEGFA (19,003-1-AP; Proteintech), α-SMA (14,395-1-AP; Proteintech), HIF-1α (20,960-1-AP; Proteintech), E-cadherin (20,874-1-AP; Proteintech), STAT3 (10,253-2-AP; Proteintech), and p-STAT3 (AP0705; ABclonal).
Techniques: Expressing, In Vitro, Western Blot, Control